Page results
-
This leaflet explains what strong opioid patches are, and how they are used for pain relief at UCLH.
-
Postnatal care should be a continuation of the care the woman has received through her pregnancy, labour and birth and take into account the woman’s individual needs and preferences.
-
This page explains how PIFU will work for you once you have finished your treatment for lymphoma.
-
An ambitious project has helped make the University College Hospital Outpatients Department much more pleasant and easy to navigate.
-
Information about activating your MyCare UCLH app.
-
This page explains what vaginal dilation therapy is and includes a step-by-step guide to how it should be performed. If you have any questions, please talk to your healthcare team.
-
UCLH today marks International Clinical Trials Day, which this year coincides with the National Institute for Health Research (NIHR) campaign encouraging everyone to ‘Be Part of Research.’
-
This page has been written for parents, carers and family members who are acting as carers and comforters for children and young people having radioactive mIBG and topotecan (MATIN) treatment.
-
This page is for parents, carers and relatives whose child is having radiotherapy treatment to a part of the brain. This page breaks down the side effects your child may experience during and after treatment, and how best to cope with them.
-
This page is for parents and carers whose child is having radiotherapy treatment to the chest, or mediastinum.
File results
-
FOI/2022/0171 - Consultant-led Referral to Treatment (RTT), outpatients and Patient Initiated Follow-up (PIFU)
-
FOI/2022/0172 - Contraceptive pill data
-
FOI/2022/0174 - Clinical systems for bed management, diagnostic reporting, discharge letters, and integration platform systems
-
FOI/2022/0177 - Assessment and treatment unit for mental health and learning disabilities
-
FOI/2022/0186 - Gender neutral toilets at the Trust
-
FOI/2022/0187 - Intra-operative cell salvage procedures
-
FOI/2022/0189 - Drug treatments for Revolade, Nplate, Doptelet, and Tavlesse
-
FOI/2022/0190 - Spend on private healthcare providers for staff
-
FOI/2022/0192 - Drug treatment for Melanoma patients
-
FOI/2022/0193 - Drug treatment for breast cancer